Wikipedia -WSS

Wikipedia

author：Wikipedia 2025-09-06 04:37:01 - browse：63949

Two hands hold a box of four Wegovy pens — first opinion coverage from STAT — Cydni Elledge/The New York Times

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Yet beneath the hype lies a real fear. Unless we reverse the rising tide of metabolic syndrome, Medicare will be crushed, with tens of millions of Americans having shorter, harder lives. The new drugs offer the first real chance to deploy at scale treatments to halt a seemingly unstoppable trend.

That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering. Beneficiaries with two or more of the costliest conditions — diabetes, heart failure, or chronic kidney disease — comprise just 10% of beneficiaries, according to the NIH’s Renal Data System 2022 Annual Data Report. Yet they account for 25% of total costs. Those with all three conditions are 2% of beneficiaries but almost 7% of costs. And remember, the current cohort of Medicare beneficiaries turned 65 when obesity and diabetes rates were lower, meaning unless we do something dramatic, and fast, these percentages will balloon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： MassMutual is introducing free genetic testing for members

WSS

Q&A: Jennifer Adair on making gene therapy available globally

Key Senate committee drafts bipartisan bill to stem drug shortages

Close Medicare's dangerous gaps in addiction treatment coverage

H5N1 bird flu found in pasteurized milk: what we know

Medical bills so high, Medicare adding extra digits to claim forms

Getting Alzheimer's drug Leqembi to patients can be a challenge

hotspot

Wikipedia

entertainment

In age of alternative facts, a scholarly course on calling out crap

Getting Alzheimer's drug Leqembi to patients can be a challenge

Novavax promises a turnaround & Lilly roils the obesity market

After traumatic brain injury, life support decisions can use more time

Medicare details structure of new drug price negotiation program

Cholera vaccine supply gets boost as demand surges globally

After affirmative action ruling, medical educators look to 'holistic review'

Sophia Smith scores twice for US in in 3

Hollywood unions extend contract negotiations for actors

Men with early prostate cancer can safely opt out of treatment

leisure time

Diversity in clinical trials starts with building trust, experts say

UnitedHealth financials solid despite Change Healthcare cyberattack

Novartis develops a rapidly manufactured CAR

Men with early prostate cancer can safely opt out of treatment

4 missing after record

FDA approves first blood sugar monitor without finger pricks

explore

focus

explore

hotspot